Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA).

ESMO gastrointestinal oncology·2026
Same author

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

ESMO gastrointestinal oncology·2026
Same author

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors.

ESMO open·2026
Same author

Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies.

ESMO open·2026
Same author

European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'.

ESMO gastrointestinal oncology·2026
Same author

German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus-version 4.0.

ESMO gastrointestinal oncology·2026

Related Experiment Video

Updated: Jun 19, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

[Principles of neoadjuvant therapy].

F Lordick1

  • 1Medizinische Klinik III, Innere Medizin, Hämatologie und Onkologie, Klinikum Braunschweig, Celler Strasse 38, 38114, Braunschweig, Deutschland. medklinik3@klinikum-braunschweig.de

Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|October 9, 2009
PubMed
Summary

Neoadjuvant therapy improves outcomes for locally advanced esophageal and stomach cancers by shrinking tumors and eradicating micrometastases. This approach enhances curative resection rates and reduces recurrence, ultimately improving overall survival.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 19, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Oncology
  • Gastrointestinal Surgery
  • Medical Oncology

Context:

  • Locally advanced cancer of the esophagus and stomach requires multimodal treatment strategies.
  • Neoadjuvant therapy is increasingly recognized as a critical component in managing these complex cases.
  • Optimizing treatment before surgery is essential for improving patient prognosis.

Purpose:

  • To review the principles and clinical application of neoadjuvant therapy for esophageal and stomach cancers.
  • To summarize the evidence supporting neoadjuvant therapy's benefits in improving surgical outcomes and survival.
  • To discuss current and future perspectives in neoadjuvant treatment strategies.

Summary:

  • Neoadjuvant therapy aims to downsize primary tumors, improve pathological staging (T and N categories), and eliminate micrometastastatic disease.
  • Clinical studies demonstrate that neoadjuvant therapy increases the rate of curative (R0) resections.
  • This preoperative treatment reduces the incidence of systemic recurrences and enhances overall survival.

Impact:

  • Neoadjuvant therapy is integral to the management of locally advanced esophageal and stomach cancers.
  • It offers a significant survival benefit and improved rates of complete tumor removal.
  • Ongoing research continues to refine and expand the role of neoadjuvant approaches in gastrointestinal oncology.